High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
BACKGROUND/AIM: Pancreatic cancer cells release certain tissue factors into the bloodstream. It is well known that pancreatic cancer progresses with thrombus formation. Because we routinely measure serum D-dimer levels in preoperative patients as a screening marker of deep venous thrombosis, we examined its association with high serum D-dimer in our cohort of pancreatic cancer resected cases.
PATIENTS AND METHODS: We examined 315 patients with pancreatic ductal adenocarcinoma who underwent surgical resection in our department from January 2012 to July 2021. All cases were divided into high D-dimer cases (n=118) and low D-dimer cases (n=197) using the cut-off value of 1.0 μg/ml, an institutional upper limit. Clinicohistological characteristics and postoperative survival outcomes were evaluated.
RESULTS: Preoperative high D-dimer cases showed significantly worse progression-free survival (PFS) (p=0.021) and overall survival (OS) (p=0.027) than low D-dimer cases; median PFS was 13.9 months versus 21.4 months, and that of OS was 33.4 months versus 68.0 months. Clinicohistological characteristics of high D-dimer cases were age over 70 years (p<0.001), pathological portal vein invasion (p=0.003), and initially borderline resectable or unresectable cases (p=0.027). Multivariate analysis indicated that preoperative high D-dimer was a significant prognostic factor of PFS (hazard ratio=1.42, p=0.025) and OS (hazard ratio=1.51, p=0.036).
CONCLUSION: Preoperative high serum D-dimer over 1.0 μg/ml was associated with pathological portal vein invasion and could be an unfavorable prognostic marker of PFS and OS after surgery, typically due to distant metastasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Anticancer research - 43(2023), 7 vom: 23. Juli, Seite 3173-3181 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Otsu, Tomohisa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
D-dimer |
|---|
| Anmerkungen: |
Date Completed 26.06.2023 Date Revised 13.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.21873/anticanres.16491 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358533783 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358533783 | ||
| 003 | DE-627 | ||
| 005 | 20231227131338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/anticanres.16491 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM358533783 | ||
| 035 | |a (NLM)37352000 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Otsu, Tomohisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.06.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
| 520 | |a BACKGROUND/AIM: Pancreatic cancer cells release certain tissue factors into the bloodstream. It is well known that pancreatic cancer progresses with thrombus formation. Because we routinely measure serum D-dimer levels in preoperative patients as a screening marker of deep venous thrombosis, we examined its association with high serum D-dimer in our cohort of pancreatic cancer resected cases | ||
| 520 | |a PATIENTS AND METHODS: We examined 315 patients with pancreatic ductal adenocarcinoma who underwent surgical resection in our department from January 2012 to July 2021. All cases were divided into high D-dimer cases (n=118) and low D-dimer cases (n=197) using the cut-off value of 1.0 μg/ml, an institutional upper limit. Clinicohistological characteristics and postoperative survival outcomes were evaluated | ||
| 520 | |a RESULTS: Preoperative high D-dimer cases showed significantly worse progression-free survival (PFS) (p=0.021) and overall survival (OS) (p=0.027) than low D-dimer cases; median PFS was 13.9 months versus 21.4 months, and that of OS was 33.4 months versus 68.0 months. Clinicohistological characteristics of high D-dimer cases were age over 70 years (p<0.001), pathological portal vein invasion (p=0.003), and initially borderline resectable or unresectable cases (p=0.027). Multivariate analysis indicated that preoperative high D-dimer was a significant prognostic factor of PFS (hazard ratio=1.42, p=0.025) and OS (hazard ratio=1.51, p=0.036) | ||
| 520 | |a CONCLUSION: Preoperative high serum D-dimer over 1.0 μg/ml was associated with pathological portal vein invasion and could be an unfavorable prognostic marker of PFS and OS after surgery, typically due to distant metastasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a D-dimer | |
| 650 | 4 | |a pancreatic cancer | |
| 650 | 4 | |a surgery | |
| 650 | 4 | |a survival outcomes | |
| 650 | 7 | |a fibrin fragment D |2 NLM | |
| 650 | 7 | |a Fibrin Fibrinogen Degradation Products |2 NLM | |
| 700 | 1 | |a Hayashi, Masamichi |e verfasserin |4 aut | |
| 700 | 1 | |a Takami, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Inokawa, Yoshikuni |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Nobutake |e verfasserin |4 aut | |
| 700 | 1 | |a Kurimoto, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nakanishi, Koki |e verfasserin |4 aut | |
| 700 | 1 | |a Umeda, Shinichi |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Hattori, Norifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Mitsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Chie |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Goro |e verfasserin |4 aut | |
| 700 | 1 | |a Kodera, Yasuhiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 43(2023), 7 vom: 23. Juli, Seite 3173-3181 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:7 |g day:23 |g month:07 |g pages:3173-3181 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/anticanres.16491 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 7 |b 23 |c 07 |h 3173-3181 | ||